Document is current
Any future updates will be listed below
-
Authors
Herrera-Luis, Esther
Li, Annie
Mak, Angel C. Y.
Perez-Garcia, Javier
Elhawary, Jennifer R.
Oh, Sam S.
Hu, Donglei
Eng, Celeste
Keys, Kevin L.
Huntsman, Scott
Beckman, Kenneth B.
Borrell, Luisa N.
Rodriguez-Santana, Jose
Burchard, Esteban G.
Pino-Yanes, Maria https://orcid.org/0000-0003-0332-437X
-
Funding
Funding for this research was provided by:
ministerio de ciencia e innovación (SAF2017-83417R, PID2020-116274RB-I00, RYC-2015-17205, PRE2018-083837)
Spanish ministry of universities (FPU19/02175)
sandler foundation
national heart, lung, and blood institute (R01HL135156, R01HL117004, R01HL128439, R01HL135156, X01HL134589, 3R01HL117004-01S3, HHSN268201600032I, 3R01HL-117626-02S1, R01HL-120393, U01HL-120393)
ucsf bakar computational health sciences institute
gordon and betty moore foundation (GBMF3834)
alfred p. sloan foundation (2013-10-27)
tobacco-related disease research program (24RT-0025, 27IR-0030))
american asthma foundation
amos medical faculty development program from the robert wood johnson foundation
harry wm. and diana v. hind distinguished professorship in pharmaceutical sciences ii
national institute of health and environmental health sciences (R01ES015794, R21ES24844)
national institute on minority health and health disparities (R01MD010443, R56MD013312)
the centers for common disease genomics of the genome sequencing program (UM1 HG008901)
national human genome research institute, the national heart, lung, and blood institute, and the national eye institute (U24 HG008956)
- License Information
-
More Information
Article History
Received: 21 June 2021
Accepted: 3 January 2022
First Online: 15 January 2022
Declarations
:
: GALA II was approved by the Human Research Protection Program Institutional Review Board of the University of California, San Francisco (ethics approval numbers: 217802). Participants/parents provided written assent/consent, respectively.
: Not applicable.
: MP-Y report grants from MCIN/AEI/10.13039/50110001103. MP-Y also reports grant support from GlaxoSmithKline, Spain through Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC) for a project outside the submitted work. MP-Y, EH-L and JP-G report funding from MCIN/AEI/10.13039/501100011033 and by “ESF Investing in your future.” EGB reports grants from the National Institutes of Health, the Tobacco-Related Disease Research Program, the Sandler Family Foundation, the American Asthma Foundation, the Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation, and from the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II. KLK reports grants from the National Institutes of Health, the Gordon and Betty Moore Foundation, and the Alfred P. Sloan Foundation. Additionally, KLK owns stock in Ambys Medicines.
